Welcome to our dedicated page for Usana Health Sciences SEC filings (Ticker: USNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
USANA Health Sciences, Inc. (NYSE: USNA) files a range of documents with the U.S. Securities and Exchange Commission that provide detail on its nutrition-focused business, financial condition, and governance. This page centralizes those SEC filings and pairs them with AI-powered summaries to help readers interpret the information more efficiently.
USANA’s current reports on Form 8-K include disclosures about preliminary financial results, updated net sales guidance, and leadership transitions, such as changes in the Chief Executive Officer role. Other 8-K filings describe credit agreements, financial covenants, and the posting of Management Commentary documents and conference call details related to quarterly results. These filings complement the company’s earnings releases and provide context on how management views performance in its direct selling and direct-to-consumer segments.
Investors can also use this page to access USANA’s periodic reports, including annual reports on Form 10-K and quarterly reports on Form 10-Q, where available. These documents typically contain segment information, risk factor discussions, and explanations of non-GAAP measures such as Adjusted EBITDA and Adjusted diluted earnings per share, which USANA references in its communications.
Stock Titan’s platform enhances these filings with AI-generated highlights that explain key sections, summarize complex tables, and surface notable items such as changes in outlook, capital structure, or significant agreements. Users can quickly locate information on topics like net sales trends, credit facilities, or integration costs related to acquisitions such as Hiya, and can review insider-related disclosures when Forms 3, 4, or 5 are filed. Real-time updates from EDGAR help ensure that new USANA filings appear promptly with concise explanations.
USANA Health Sciences (USNA) reported an insider stock acquisition by a director. On 10/23/2025, the director acquired 1,057 shares of common stock through the settlement of restricted stock units, coded M (derivative conversion).
The shares were delivered at a stated price of $0. Following the transaction, the director beneficially owns 7,986 shares directly, with 2,115 RSUs remaining outstanding. Each RSU represents the right to receive one share of USNA common stock. The RSUs vest in four 25% installments on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed a Form 4 showing a director acquired 1,057 shares of common stock on 10/23/2025 via transaction code M, reflecting the settlement of restricted stock units into shares.
Following the transaction, the director beneficially owned 7,698 common shares directly. The filing also shows 2,115 restricted stock units beneficially owned after the event, with vesting scheduled at 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The derivative security price is listed as $0, consistent with RSU settlement.
USANA Health Sciences (USNA) reported a director’s acquisition of 1,057 shares of common stock on 10/23/2025, coded “M” for settlement of restricted stock units.
After the transaction, the reporting person beneficially owns 1,057 shares directly and 2,115 restricted stock units. The RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences (USNA) disclosed an insider transaction by a director on 10/23/2025. The filing reports the acquisition of 1,057 shares of common stock via the settlement of restricted stock units (Transaction Code M). Following the transaction, the reporting person directly owns 6,315 common shares and holds 2,115 restricted stock units.
The RSUs vest in four equal installments of 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026. The RSU settlement carried a stated price of $0 for the underlying common shares, consistent with equity award vesting mechanics.
USANA Health Sciences (USNA) disclosed insider activity dated 10/23/2025. A director acquired 1,057 shares of common stock through the conversion of restricted stock units (code M) and disposed of 476 shares (code F) at $20.63.
After the transactions, the director beneficially owned 5,918 common shares directly and held 2,115 restricted stock units. These RSUs vest 25% on July 24, 2025, October 23, 2025, January 22, 2026, and April 23, 2026.
USANA Health Sciences furnished an update on investor communications. The company announced a press release with financial results for the third quarter ended September 27, 2025, and said it will post a “Management Commentary” on its website. Executives will host a conference call with brief remarks followed by Q&A, with webcast and telephone access details provided.
The press release and Management Commentary are included as Exhibits 99.1 and 99.2 and are furnished, not filed. These materials will be available on www.usana.com.
USANA Health Sciences, Inc. filed a current report to let investors know it has released a press release with preliminary financial results for its third quarter ended September 27, 2025. The company is furnishing this information under the sections covering results of operations and Regulation FD, and it attaches the press release as Exhibit 99.1. The disclosure is classified as “furnished” rather than “filed,” which limits its use for certain legal purposes but still makes the preliminary quarterly results publicly available.
Dimensional Fund Advisors LP reports holding 915,049 shares of USANA Health Sciences Inc common stock, representing
The statement clarifies these holdings arise from Dimensional’s advisory roles to registered investment companies, commingled funds, group trusts and separate accounts and that no single Fund listed is known to hold more than
Myron W. Wentz, a director and >10% owner of USANA Health Sciences (USNA), reported a sale of 145,000 shares of Common Stock. After the reported disposition, the filing shows beneficial ownership of 7,408,345 shares held indirectly through Gull Global Limited, an entity Dr. Wentz indirectly owns and controls. The filing also explains Gull Global Limited is owned 50% by Viron Company Limited and 50% by Myogen Limited, each ultimately controlled by Dr. Wentz. The disclosure is limited to the change in share count and the ownership chain; no option or derivative transactions are reported.
USANA Health Sciences (USNA) filer submitted a Form 144 proposing the sale of 5,169 common shares through Morgan Stanley Smith Barney on the NYSE. The shares have an aggregate market value of $165,408 and the issuer reports 18,271,836 shares outstanding, making the sale a small fraction of total shares. The shares were acquired as restricted stock in early February 2025 (944 on 02/07/2025, 2,805 on 02/08/2025 and 1,420 on 02/06/2025) and the approximate sale date is listed as 08/28/2025. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
FAQ
What is the current stock price of Usana Health Sciences (USNA)?
What is the market cap of Usana Health Sciences (USNA)?
